AXLA · Axcella Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.22M | $1.43M | - | $13.32M | $16.87M | $13.54M | - | $10.13M | $10.30M | $10.24M |
| SG&A | $2.32M | $2.75M | - | $3.78M | $3.75M | $4.79M | - | $4.77M | $4.95M | $4.26M |
| Total Operating Expenses | $3.54M | $4.18M | - | $17.09M | $20.62M | $18.33M | - | $14.90M | $15.24M | $14.50M |
| D&A | $100.0K | $11.0K | - | - | - | $77.0K | - | - | - | $64.0K |
| Operating Income | ($3.54M) | ($4.18M) | - | ($17.09M) | ($20.62M) | ($18.33M) | - | ($14.90M) | ($15.24M) | ($14.50M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.41M) | ($3.98M) | - | ($17.84M) | ($21.31M) | ($19.04M) | - | ($15.61M) | ($15.94M) | ($15.19M) |
| EPS - Basic | ($0.05) | ($0.05) | - | ($0.34) | ($0.40) | ($0.40) | - | ($0.41) | ($0.42) | - |
| EPS - Diluted | ($0.05) | ($0.05) | - | ($0.34) | ($0.40) | ($0.40) | - | ($0.41) | ($0.42) | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.88M | $12.54M | $17.15M | $25.43M | $34.08M | $45.19M | $23.57M | $26.09M | $33.94M | $43.05M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.39M | $8.15M | $4.71M | $3.63M | $4.00M | $4.84M | $4.30M | $2.98M | $2.30M | $1.54M |
| Current Assets | $9.27M | $12.74M | $18.02M | $27.23M | $46.14M | $64.18M | $56.65M | $67.67M | $80.26M | $93.94M |
| Total Assets | $9.28M | $12.77M | $18.93M | $30.79M | $49.98M | $68.38M | $57.73M | $68.82M | $81.48M | $94.48M |
| Current Liabilities | $11.54M | $11.89M | $14.15M | $22.11M | $17.18M | $12.94M | $10.15M | $7.76M | $12.03M | $10.47M |
| Long-term Debt | - | - | $0 | $15.13M | $21.70M | $23.39M | $25.07M | $25.02M | $19.63M | $25.22M |
| Total Liabilities | $11.54M | $12.04M | $14.76M | $38.34M | $40.68M | $38.49M | $35.72M | $33.26M | $33.40M | $32.82M |
| Stockholders' Equity | ($2.26M) | $727.0K | $4.16M | ($7.55M) | $9.30M | $29.89M | $22.01M | $35.56M | $48.09M | $61.66M |
| Retained Earnings | ($425.82M) | ($422.40M) | ($418.43M) | ($395.43M) | ($377.59M) | ($356.28M) | ($337.24M) | ($319.35M) | ($303.74M) | ($287.80M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.80M) | ($5.11M) | - | - | ($35.50M) | ($16.86M) | - | - | - | ($14.14M) |
| Investing Cash Flow | - | $525.0K | - | - | - | $13.16M | - | - | - | ($14.39M) |
| Financing Cash Flow | - | ($27.0K) | - | - | - | $25.32M | - | - | - | ($4.0K) |
| CapEx | - | $0 | - | - | - | $164.0K | - | - | - | $50.0K |
| Free Cash Flow | - | ($5.11M) | - | - | - | ($17.03M) | - | - | - | ($14.20M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 1.28 | - | - | - | 0.89 | - | - | - | 0.93 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -36.8% | -31.1% | - | -57.9% | -42.6% | -27.8% | - | -22.7% | -19.6% | -16.1% |
| Return on equity | 151.2% | -546.9% | - | 236.2% | -229.1% | -63.7% | - | -43.9% | -33.1% | -24.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.80 | 1.07 | 1.27 | 1.23 | 2.69 | 4.96 | 5.58 | 8.72 | 6.67 | 8.97 |
| Quick ratio | 0.80 | 1.07 | 1.27 | 1.23 | 2.69 | 4.96 | 5.58 | 8.72 | 6.67 | 8.97 |
| Cash ratio | 0.77 | 1.05 | 1.21 | 1.15 | 1.98 | 3.49 | 2.32 | 3.36 | 2.82 | 4.11 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 0.00 | -2.00 | 2.33 | 0.78 | 1.14 | 0.70 | 0.41 | 0.41 |
| Debt / Assets | - | - | 0.00 | 0.49 | 0.43 | 0.34 | 0.43 | 0.36 | 0.24 | 0.27 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -4.11 | 17.56 | 4.55 | -4.08 | 5.38 | 2.29 | 2.62 | 1.94 | 1.69 | 1.53 |
| Liabilities / Assets | 1.24 | 0.94 | 0.78 | 1.25 | 0.81 | 0.56 | 0.62 | 0.48 | 0.41 | 0.35 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 82.8% | 77.2% | - | -14.7% | -35.3% | -26.4% | - | -27.1% | -15.6% | -0.2% |
| Net income growth (YoY) | 84.0% | 79.1% | - | -14.3% | -33.7% | -25.3% | - | -25.5% | -14.7% | -1.2% |
| EPS growth (YoY) | 87.5% | 87.5% | - | 17.1% | 4.8% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 70.0% | - | - | - | -19.9% | - | - | - | 14.1% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -97.6% | -81.1% | - | -80.7% | -51.5% | -70.8% | -59.9% | -48.3% | 31.7% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Axcella Health Inc. against the 5 most active filers in the same SIC group.